More than 15,000 people — firefighters, military veterans, and airport workers — are waiting for answers in one of the most consequential toxic exposure litigations in American history. The AFFF lawsuit docket inside MDL 2873 has reached a record 15,240 active personal injury claims as of June 2026, yet the landmark bellwether trial that was supposed to begin October 20, 2025 was quietly removed from the calendar. No replacement date has been set. Billions of dollars have already flowed to municipal water systems. Not one dollar of that money has reached an individual cancer patient. This article explains exactly where the litigation stands, what caused the delay, and how claimants can begin estimating their potential compensation right now.
What Is the AFFF Lawsuit and Who Is Affected?
Aqueous film-forming foam — commonly called AFFF — is a firefighting suppressant that was originally developed through a collaboration between the U.S. military and 3M, with the underlying chemistry patented as far back as 1965. For decades, AFFF was the standard tool for combating fuel fires at military installations, commercial airports, and training facilities across the country. The problem is that AFFF contains per- and polyfluoroalkyl substances, or PFAS — a class of synthetic compounds that do not break down in the human body or the environment, earning them the nickname “forever chemicals.”
The two most studied PFAS compounds in AFFF are PFOA and PFOS, both of which have been linked by scientific and regulatory bodies to a range of serious illnesses. The Centers for Disease Control and Prevention has identified occupational PFAS exposure as a significant public health concern, particularly for first responders. Recognized injury categories in MDL 2873 currently include kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and liver cancer. Research by the National Cancer Institute found a statistically significant association between PFAS exposure and testicular cancer specifically, while studies consistently show that firefighters carry triple the PFAS blood concentrations of the general population.
The defendants named across the AFFF lawsuit include some of the largest chemical and fire-safety manufacturers in the world: 3M, DuPont de Nemours, Chemours, Tyco Fire Products, Kidde-Fenwal, BASF, and others. The U.S. Department of Defense required military installations to stop using AFFF as of October 1, 2024, but the human damage from decades of prior exposure is only now fully emerging in courtrooms. A 2023 U.S. Geological Survey analysis estimated that as many as 45 percent of all U.S. tap water sources may contain detectable PFAS levels, underscoring just how widespread contamination has become.
The State of MDL 2873: A Record Docket Frozen at a Critical Moment
MDL 2873 was centralized in the U.S. District Court for the District of South Carolina in December 2018, beginning with just 75 cases before Judge Richard M. Gergel. By June 2026, that number has grown to 15,240 active personal injury claims — the highest caseload the docket has ever carried. The explosive growth is itself one reason the first personal injury bellwether trial was postponed: a surge in new filings in mid-2025 triggered additional administrative processing requirements that Judge Gergel addressed through a September 5, 2025 filing facilitation window, which ordered bundled complaints of up to 150 plaintiffs and standardized short-form complaints to manage the volume.
The bellwether trial that had been scheduled for October 20, 2025, was focused narrowly on kidney cancer — a deliberate choice by Judge Gergel to present jurors with a single, well-defined injury rather than multiple overlapping conditions. The bellwether pool was drawn from 25 plaintiffs exposed at two specific contamination sites, and plaintiff attorneys had requested consolidating five kidney and testicular cancer cases connected to the former Naval Air Station Joint Reserve Base Willow Grove and the Warminster Naval Air Weapons Center in Pennsylvania into a single proceeding. That trial is now off the calendar with no replacement date announced as of June 2026.
What makes this moment especially significant is that the science phase of the litigation is essentially complete. A Science Day for liver and thyroid cancer causation was held June 20, 2025, under Case Management Order No. 33, completing expert testimony proceedings across all six recognized injury categories. Federal court docket records from the District of South Carolina confirm that Daubert rulings — the gatekeeping decisions about which expert witnesses and scientific methodologies will be permitted at trial — are expected to be pivotal once a new bellwether date is established. Leadership attorney teams for both plaintiffs and defendants have been extended through May 2026, signaling that active negotiation and preparation continue even without a trial date on the horizon.
The Municipal Settlement Gap: Billions Paid Out — None to Cancer Patients
Perhaps the most frustrating reality for the 15,240 individual claimants in the AFFF lawsuit is watching enormous sums change hands while their own claims remain unresolved. The municipal water system track of this litigation has produced landmark results: 3M agreed to pay approximately $10.3 billion to public water systems, while DuPont, Chemours, and Corteva settled with water utilities for $1.185 billion. In August 2025, New Jersey separately secured an $875 million PFAS settlement from DuPont, Chemours, and Corteva for state environmental cleanup costs.
These are extraordinary numbers — but they compensate governments and utilities for contamination remediation costs. Not one dollar of those municipal settlements flows to an individual cancer patient. The personal injury track of MDL 2873 has produced zero global settlement as of June 2026. The contrast between the resolution of institutional claims and the stalling of individual human injury claims is the central tension defining this litigation right now. Judge Gergel has publicly urged defendants to pursue settlement, and attorneys widely expect a global personal injury resolution in 2026 or 2027 once the bellwether is rescheduled and Daubert rulings clarify the evidentiary landscape at trial.
One data point illustrates just how high individual verdicts can reach: DuPont was previously ordered to pay $50 million to a single testicular cancer victim in a PFOA drinking water case, establishing a powerful precedent for what juries may award when personal causation is proven. That verdict — combined with the now-complete science phase in MDL 2873 — gives plaintiff attorneys significant leverage heading into any global settlement negotiation. If you are tracking this litigation as a claimant or potential claimant, a personal injury settlement calculator can help you develop a preliminary range for your individual claim based on injury type, exposure history, and other factors.
AFFF Settlement Value: What Individual Claims Could Be Worth
Estimating individual compensation in a mass tort of this scale requires understanding how courts and defendants approach tiered settlement structures. In the AFFF lawsuit, settlement value is expected to vary substantially based on several factors: the specific cancer diagnosis or qualifying illness, the duration and intensity of PFAS exposure, the claimant’s age at diagnosis, the strength of medical documentation, and whether the claimant can demonstrate a direct link to a contaminated site or occupation.
| Injury Category | Estimated Settlement Range | Notes |
|---|---|---|
| Kidney Cancer | $200,000 – $500,000+ | First bellwether focus; strong causation science |
| Testicular Cancer | $200,000 – $1,000,000+ | NCI association data; younger claimants common |
| Thyroid Disease / Cancer | $75,000 – $300,000 | Science Day completed June 2025 |
| Liver Cancer | $150,000 – $500,000+ | Daubert proceedings completed; severity dependent |
| Ulcerative Colitis | $75,000 – $250,000 | Recognized qualifying condition in MDL 2873 |
Ranges reflect industry estimates from multiple litigation monitoring sources. Individual results depend on case-specific factors and are not guaranteed. Severe cases with documented long-term exposure and advanced-stage diagnosis may exceed published upper estimates.
Industry estimates generally place individual AFFF lawsuit payouts in the range of $75,000 to $500,000, while legal analysts project that severe cases — particularly those involving advanced cancers with strong occupational exposure documentation — could reach $1,000,000 or more. The EPA’s finalization of maximum contaminant levels for PFOA and PFOS at 4 parts per trillion, established under the Safe Drinking Water Act regulatory framework, also strengthens the legal foundation for claimants who can show exposure above that threshold. For claimants whose AFFF exposure involved medical device or pharmaceutical product interactions, a medical malpractice calculator may provide additional context for overlapping injury claims.
What Happens Next in the AFFF Litigation Timeline
The path forward in MDL 2873 runs through several sequenced events. First, Judge Gergel must set a new bellwether trial date — a step that litigation watchers expect will occur in the second half of 2026 at the earliest. Once a date is set, Daubert motions challenging plaintiff and defense expert witnesses on causation will likely be heard and ruled upon, a process that could take months but will ultimately define what science the jury hears. If plaintiff experts survive Daubert scrutiny — which the completed Science Day proceedings suggest is plausible — defendant settlement pressure will intensify sharply.
Tens of thousands of additional viable claims are estimated to remain unfiled. Judge Gergel held an urgent status conference in July 2025 specifically to address the processing backlog, and the September 2025 facilitation window was a direct response to that pressure. The leadership team extensions through May 2026 on both sides indicate that global settlement architecture is being actively discussed even without a trial date. Federal Rule of Civil Procedure 16 gives MDL judges broad authority to facilitate settlement conferences, and Judge Gergel has already signaled his intent to use that authority aggressively.
For claimants and their families, the practical advice from litigation monitoring sources is consistent: preserve all medical records documenting diagnosis and treatment, compile employment history and service records demonstrating AFFF exposure, and stay in communication with retained counsel as the bellwether rescheduling process develops. The absence of a trial date does not mean the litigation is stalled — it means the most consequential negotiations are likely happening outside the public docket right now. In cases where an AFFF-related death has occurred, families should also explore a wrongful death calculator to understand potential compensation for surviving dependents.
Frequently Asked Questions About the AFFF Lawsuit in 2026
Why was the October 2025 AFFF bellwether trial canceled, and when will it be rescheduled?
The first personal injury bellwether trial, which had been set for October 20, 2025, was removed from the calendar after a surge in new case filings created administrative processing demands that required Judge Gergel to implement a structured filing facilitation system. The surge — which pushed active personal injury cases to a record 15,240 — required bundled complaint procedures and short-form filing protocols before the case pool could be finalized for trial selection. As of June 2026, no new trial date has been announced. Most litigation analysts expect a rescheduled date to be set in late 2026, with the trial itself potentially occurring in 2027 depending on Daubert motion timelines.
Who qualifies to file an AFFF lawsuit claim in 2026?
Individuals who may qualify include military veterans who served at bases where AFFF was used in firefighting training or emergency response, civilian and military firefighters with documented AFFF exposure, airport workers and crash-rescue personnel who used AFFF on the job, and residents or workers who lived near contaminated military or industrial sites. The qualifying diagnoses recognized in MDL 2873 are kidney cancer, testicular cancer, thyroid disease or cancer, ulcerative colitis, and liver cancer. Claimants generally need to demonstrate both a qualifying diagnosis and a documented exposure history. Tens of thousands of eligible individuals are estimated to have not yet filed claims.
Have any AFFF settlements paid money to individual cancer patients yet?
As of June 2026, no global personal injury settlement has been reached in the AFFF MDL, and no individual cancer claimants have received compensation through the MDL personal injury track. The billions of dollars that have been paid out — including 3M’s approximately $10.3 billion settlement and DuPont and Chemours’s $1.185 billion settlement — were directed exclusively to municipal water systems and government entities for remediation costs. Individual cancer patients are in a separate litigation track that has not yet produced any resolution. This distinction is critical: the headline settlement figures do not benefit personal injury claimants.
How much could an individual AFFF lawsuit settlement be worth?
Individual settlement values in the AFFF lawsuit are expected to vary widely based on injury type, cancer stage at diagnosis, age, documented exposure duration, and the strength of causation evidence. Industry estimates place the typical range between $75,000 and $500,000, while legal analysts project that severe cancer cases with strong documentation could reach $1,000,000 or more. Testicular cancer cases involving younger claimants with long occupational exposure have drawn the highest projections. A prior jury verdict of $50 million against DuPont for a single testicular cancer victim in a related PFOA case demonstrates that individual verdicts can be substantial. Settlement values in a global resolution will depend significantly on how Daubert rulings and the rescheduled bellwether trial unfold.
What should AFFF claimants do while waiting for the bellwether to be rescheduled?
Claimants should take several proactive steps during the current waiting period. First, compile and preserve all medical records documenting the diagnosis, treatment history, and prognosis for any qualifying condition. Second, gather military service records, employment records, or other documentation that establishes the timeline and location of AFFF exposure — this is often the most critical piece of evidence in establishing causation. Third, maintain regular communication with your retained attorney, as case management orders and Daubert rulings can affect individual case positioning within the settlement pool. Fourth, if you have not yet filed a claim despite having a qualifying diagnosis and exposure history, consult a qualified attorney promptly — the filing facilitation windows established by Judge Gergel are specifically designed to accommodate new claimants during this phase of the litigation.
This content is provided for informational purposes only and does not constitute legal advice or create an attorney-client relationship.
Related reading: GLP-1 Vision Loss Lawsuit Damages: How NAION Blindness Cases Are Valued Against Novo Nordisk & Eli Lilly
Related reading: The Forensic Economist In A Wrongful Death Case: How An Expert Witness Builds — And Defends — Every Dollar Of Economic Damages
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.